ARC-T Cells Plus SPRX002

Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome, Including Long-term Safety Follow-up

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
24 patients (estimated)
Sponsors
Arcellx, Inc.
Tags
CAR T Cell, CD123
Trial Type
Treatment
Last Update
4 weeks ago
SparkCures ID
1570
NCT Identifier
NCT05457010

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.